Abstract
Many systemic agents are commonly used to treat generalized psoriasis. Although they are efficacious, their potential adverse effects require close monitoring. These agents can be used either alone or in combination therapy. In addition, they can be used as rotational or sequential therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Napoli JL, Boerman MH, Chai X, Zhai Y, Fiorella PD (1995) Enzymes and binding proteins affecting retinoic acid concentrations. J Steroid Biochem Mol Biol 53: 497–502
Napoli JL (1996) Retinoic acid biosynthesis and metabolism. FASEB J 10: 993–1001
Saurat JH (1999) Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 41: S2–6
Torma H, Rollman O, Vahlquist A (1998) Interferon-g increases retinoic acid and 3,4-didehydroretinoic acid concentrations in cultured keratinocytes: a clue to the abnormal vitamin A metabolism in psoriatic skin. J Invest Dermatol 110: 551
Geiger JM, Saurat JH (1993) Acitretin and etretinate. How and when they should be used. Dermatol Clin 11: 117–129
Ling MR (1999) Acitretin: optimal dosing strategies. J Am Acad Dermatol 41: S13–17
Soriatane package insert (2004) Palo Alto, CA: Connectics Corporation
Geiger JM, Czarnetzki BM (1988) Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica 176: 182–190
Camisa C (2004) Handbook of psoriasis. Publishing Ltd, Malden, MA
Lebwohl M, Ali S (2001) Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 45: 649–661
Roenigk HH (1999) Acitretin combination therapy. J Am Acad Dermatol 41: S18–21
Katz HI, Waalen J, Leach EE (1999) Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 41: S7–S12
McNamara PJ, Jewell RC, Jensen BK, Brindley CJ (1988) Food increases the bioavailability of acitretin. J Clin Pharmacol 28: 1051–1055
Nguyen EQH (2001) Systemic retinoids. In: CL Kulp-Shorten, SE Wolverton (eds): Comprehensive dermatologic drug therapy. WB Saunders Company, Philadelphia (PA), 269–310
McClure SL, Valentine J, Gordon KB (2002) Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 25: 913–927
Roche Laboratories, data on file
Gollnick HP (1996) Oral retinoids: efficacy and toxicity in psoriasis. Br J Dermatol 135Suppl 49: 6–17
Wilson DJ, Kay V, Charig M, Hughes DG, Creasy TS (1988) Skeletal hyperostosis and extraosseous calcification in patients receiving long-term etretinate (Tigason). Br J Dermatol 119: 597–607
Yarbro JW (1969) Hydroxyurea in the treatment of refractory psoriasis. Lancet 2: 846–847
Leavell UW, Yarbro JW (1970) Hydroxyurea. A new treatment for psoriasis. Arch Dermatol 102: 144–150
Yamauchi PS, Rizk D, Kormeili T, Patnail R, Lowe NJ (2003) Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 49: S66–77
Vogler WR, Bain JA, Huguley CM (1966) In vivo effect of hydroxyurea on orotic acid synthesis. Cancer Res 26: 1827–1831
Klem EB (1978) Effects of antipsoriasis drugs and metabolic inhibitors on the growth of epidermal cells in culture. J Invest Dermatol 70: 27–32
Boyd AS, Neldner KH (1991) Hydroxyurea therapy. J Am Acad Dermatol 25: 518–524
Burns DA, Sarkany I, Gaylarde P (1980) Effects of hydroxyurea therapy on normal skin: a case report. Clin Exp Dermatol 5: 447–449
Kennedy BJ, Smith LR, Goltx RW (1975) Skin changes secondary to hydroxyurea therapy. Arch Dermatol 111: 183–187
Stein KM, Shelley WB, Weinberg RA (1971) Hydroxyurea in the treatment of pustular psoriasis. Br J Dermatol 85: 81–85
Wahba A, Cohen H, Bar-Eli M, Callily R (1979) Neutrophil chemotaxis in psoriasis. Acta Derm Venereol 59: 441–445
Moschella SL, Greenwald MA (1973) Psoriasis with hydroxyurea. An 18-month study of 60 patients. Arch Dermatol 107: 363–368
Layton AM, Sheehan-Dare RA, Goodfield MJ, Cotterill JA (1989) Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 121: 647–653
Kumar B, Saraswat A, Kaur I (2001) Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol 40: 530–534
Hydrea package insert (2001) Princeton, NJ: Bristol-Myers Squibb Company
Kumar B, Saraswat A, Kaur I (2002) Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol 27: 8–13
Thurman WG, Bloedow C, Howe CD, Levin WC, Davis P, Lane M, Sullivan MP, Griffith KM (1963) A phase I study of hydroxyurea. Cancer Chemother Rep 29: 103–107
Folan DW (1977) Severe reaction to hydroxyurea. Cutis 20: 95
Heddle R, Calvert AF (1980) Hydroxyurea induced hepatitis. Med J Aust 1: 121
Baker H (1982) Antimitotic drugs in psoriasis. In: EM Farber, AJ Cox (eds): Psoriasis: Proceedings of the Third International Symposium. Grune and Stratton, New York, 119–126
Samuels ML, Howe CD (1964) Renal abnormalities induced by hydroxyurea (NSC-32065) Cancer Chemother Rep 40: 9–13
Snow JL, Gibson LE (1995) The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 131: 193–197
Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M (2005) The use of systemic immune moderators in dermatology: an update. Dermatol Clin 23: 259–300
Sanderson J, Ansari A, Marinaki T, Duley J (2004) Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 41: 294–302
Patel AA, Swerlick RA, McCall CO (2006) Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 55: 369–389
35. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV (2002) Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM 95: 439–444
Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32: 651–662
du Vivier A, Munro DD, Verbov J (1974) Treatment of psoriasis with azathioprine. Br Med J 1: 49–51
Zackheim HS, Glogau RG, Fisher DA, Maibach HI (1994) 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 30: 452–458
Mason C, Krueger GG (2001) Thioguanine for refractory psoriasis: a 4-year experience. J Am Acad Dermatol 44: 67–72
Anstey AV, Wakelin S, Reynolds NJ (2004) Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 151: 1123–1132
Tabloid package insert (2004) Research Triangle Park, NC: GlaxoSmithKline
Silvis NG, Levine N (1999) Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol 135: 433–437
Imuran package insert (2001) San Diego, CA: Prometheus Laboratories, Inc.
Kao NL, Rosenblate HJ (1993) 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 28: 1017–1018
de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA (2006) Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 101: 1390–1392
de Boer NK, van Elburg RM, Wilhelm AJ, Remmink AJ, van Vugt JM, Mulder CJ, van Bodegraven AA (2005) 6-Thioguanine for Crohn’s disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand J Gastroenterol 40: 1374–1377
Norgard B, Pedersen L, Jacobsen J, Rasmussen SN, Sorensen HT (2004) The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 19: 679–685
Rajapakse RO, Korelitz BI, Zlatanic J, Baiocco PJ, Gleim GW (2000) Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 95: 684–688
Allison AC, Eugui EM (1996) Purine metabolism and immunosuppressive effects if mycophenolate mofetil (MMF). Clin Transplant 10: 77–84
Geilen CC, Arnold M, Orfanos CE (2001) Mycophenolic mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 144: 583–586
Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL (1997) Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 37: 445–449
Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P (1975) Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 65: 537–542
Lynch WS, Roenigk HH (1977) Mycophenolic acid for psoriasis. Arch Dermatol 113: 1203–1208
Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL (1977) Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol 113: 930–932
Gomez EC, Menendez L, Frost P (1979) Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1: 531–537
Epinette WW, Parker CM, Jones EL, Greist MC (1987) Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 17: 962–971
Haufs MG, Beissert S, Grabbe S, Schutte B, Luger TA (1998) Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 138: 179–181
Zhou Y, Rosenthal D, Dutz J, Ho V (2003) Mycophenolate mofetil (CellCept) for psoriasis: a twocenter, prospective, open-label clinical trial. J Cutan Med Surg 7: 193–197
CellCept package insert (2005) Nutley, NJ: Roche Laboratories
Myfortic package insert (2004) East Hanover, NJ: Novartis Pharmaceuticals Corporation
Mathew TH (1998) A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65: 1450–1454
Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC (1991) RS-61443 — a new, potent immunosuppressive agent. Transplantation 51: 27–31
Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond DH, O’Connell JB, Dunn D, Osburn L, Jones KW, Kauffman RS et al. (1993) The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 56: 75–82
Goldblum R (1993) Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exper Rheum 11: S117–119
Cohen HD, Das KM (2006) The metabolism of mesalamine and its possible use in colonic diver ticulitis as an anti-inflammatory agent. J Clin Gastroenterol 40: S150–154
Gupta AK, Ellis CN, Siegel MT, Duell EA, Griffiths CE, Hamilton TA, Nickoloff BJ, Voorhees JJ (1990) Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 126: 487–493
Gupta AK, Ellis CN, Siegel MT, Voorhees JJ (1989) Sulfasalazine: a potential psoriasis therapy? J Am Acad Dermatol 20: 797–800
Schoch EP, McCuistion CH (1955) The effect of salicylazosulfapyridine (azulfidine) on pustular acne vulgaris and certain other dermatoses. J Invest Dermatol 25: 123–126
Lorincz AL, Pearson RW (1962) Sulfapyridine and sulfone type drugs in dermatology. Arch Dermatol 85: 2–16
Azulfidine package insert (2002) Kalamazoo, MI: Pharmacia Corporation
Lebwohl M (1999) Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 41: S22–24
Weinstein GD, White GM (1993) An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 28: 454–459
Koo J (1999) Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 41: S25–28
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Shah, S.K., Weinberg, J.M. (2008). Traditional systemic therapy II: retinoids and others (hydroxyurea, thiopurine antimetabolites, mycophenlic acid, sulfasalazine). In: Weinberg, J.M. (eds) Treatment of Psoriasis. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7724-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7724-3_8
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7722-9
Online ISBN: 978-3-7643-7724-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)